Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model

Neuroinflammation is a miscreant in accelerating progression of many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). However, treatments targeting neuroinflammation alone have led to disappointing results in clinical trials. Both neuronal and non-neuronal cell types have b...

Full description

Bibliographic Details

Published in:	Molecular Therapy: Methods & Clinical Development
Main Authors:	Megan C. Baird, Shibi B. Likhite, Tatyana A. Vetter, Joseph R. Caporale, Holly B. Girard, Florence S. Roussel, Abigail E. Howard, Maura K. Schwartz, Addison R. Reed, Abuzar Kaleem, Xiaojin Zhang, Kathrin C. Meyer
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Subjects:	gene therapy combination therapy amyotrophic lateral sclerosis SOD1G93A mouse neuroinflammation AAV
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050124001281